Immunology and Microbiology
Adaptive Immune System
13%
Adoptive Immunity
22%
Autoimmune Disease
7%
Autoimmunity
12%
Bacilli
21%
BCG Vaccine
12%
Blood Plasma
7%
Booster Dose
12%
Central Nervous System
12%
COVID-19
17%
Cytokine
9%
Dendritic Cell
7%
Human Metapneumovirus
54%
Human Respiratory Syncytial Virus
78%
Humoral Immunity
25%
Immune Response
50%
Immune System
10%
Immunocompetent Cell
19%
Immunogenicity
23%
Inactivated Vaccine
13%
Infectious Agent
22%
Inflammatory Arthritis
7%
Innate Immune System
6%
interferon
15%
Interleukin 10
12%
Lower Respiratory Tract
9%
Monocyte
7%
Monospecific Antibody
17%
Mouse
34%
Mouse Model
8%
Mycobacterium bovis
12%
Mycobacterium Bovis BCG
11%
Neutralizing Antibody
19%
Neutrophil Granulocyte
8%
Normal Human
6%
Nucleoprotein
11%
Omicron Coronavirus Variant
18%
Respiratory Syncytial Virus Infection
21%
Secretion (Process)
17%
Severe Acute Respiratory Syndrome Coronavirus 2
66%
Streptococcus Agalactiae
12%
Streptococcus Pneumoniae
6%
Surface Property
14%
Systemic Lupus Erythematosus
19%
T Cell
35%
T-Helper Cell
7%
Vaccination Policy
28%
Vaccine Efficacy
99%
Viral Clearance
9%
Viral Disease
13%
Keyphrases
Adaptive Immunity
11%
Autoimmune Response
10%
Bacillus Calmette
15%
Breakthrough Cases
12%
Cellular Immune Response
13%
Cellular Response
13%
Central Nervous System
10%
Chile
24%
Clinical Trials
10%
CoronaVac
42%
COVID-19
34%
Group B Streptococcus
12%
Human Metapneumovirus (hMPV)
54%
Human Respiratory Syncytial Virus (hRSV)
100%
Humoral Immunity
12%
Humoral Response
10%
Immune Cells
12%
Immune Response
43%
Immune System
10%
Immunization
19%
Immunogenicity
19%
Inactivated SARS-CoV-2 Vaccine
16%
Inactivated Vaccine
13%
Innate Immune Response
12%
Interferon-α (IFN-α)
13%
Interleukin-10
12%
Lung
11%
Mouse Model
11%
Mycobacterium Bovis
12%
Neutralizing Antibodies
22%
Neutralizing Capacity
13%
Nucleoprotein
11%
Pediatric Population
11%
Phase III Clinical Trial
12%
Protective Immunity
12%
Recombinant BCG Vaccine
12%
Respiratory Syncytial Virus
18%
Respiratory Syncytial Virus Infection
40%
Second Dose
11%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
18%
Surface Immunogenic Protein
12%
Systemic Lupus Erythematosus
13%
T Cells
21%
Trained Immunity
16%
Two-dose
13%
Vaccination
24%
Variants of Concern
12%
Viral Clearance
9%
Viral Infection
15%
Virus
46%